Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report

Abstract Background A BRAF V600E mutation is found as driver oncogene in patients with non-small cell lung cancer. Although combined treatment with dabrafenib and trametinib is highly effective, the efficacy of reduced doses of the drugs in combination therapy has not yet been reported. Case present...

Full description

Bibliographic Details
Main Authors: Yuta Adachi, Naohiro Yanagimura, Chiaki Suzuki, Sakiko Ootani, Azusa Tanimoto, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Seiji Yano
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
BRAF V600E mutation
Dabrafenib
Trametinib
Rhabdomyolysis
Online Access:http://link.springer.com/article/10.1186/s12885-020-6626-9

Internet

http://link.springer.com/article/10.1186/s12885-020-6626-9

Similar Items